公司经营业绩变动的主要原因是：1)公司紧抓生物医药装备行业发展机遇，持续推进市场拓展与业务布 局，收入规模稳步提升;2)受市场竞争加剧、下游行业需求波动，叠加高毛利海外收入占比下降等因素 影响，公司盈利水平有所下滑。 智通财经APP讯，汉邦科技(688755.SH)披露2025年度业绩快报，2025年度实现营业总收入7.35亿元，同 比增长6.40%;归属于母公司所有者的净利润5958.75万元，同比下降24.89%。 ...

公司经营业绩变动的主要原因是：1)公司紧抓生物医药装备行业发展机遇，持续推进市场拓展与业务布 局，收入规模稳步提升;2)受市场竞争加剧、下游行业需求波动，叠加高毛利海外收入占比下降等因素 影响，公司盈利水平有所下滑。 汉邦科技(688755.SH)披露2025年度业绩快报，2025年度实现营业总收入7.35亿元，同比增长6.40%;归属 于母公司所有者的净利润5958.75万元，同比下降24.89%。 ...

格隆汇2月27日丨汉邦科技(688755.SH)公布2025年度业绩快报，2025年度，公司实现营业总收入7.35亿 元，较上年同期增长6.40%；归属于母公司所有者的净利润5958.75万元，较上年同期下降24.89%；归属 于母公司所有者的扣除非经常性损益的净利润4955.21万元，较上年同期下降34.84%。2025年末，公司 总资产19.34亿元，较报告期初增长45.96%；归属于母公司的所有者权益12.43亿元，较报告期初增长 68.03%；归属于母公司所有者的每股净资产14.12元，较报告期初上升26.02%。 公司经营业绩变动的主要原因是：1)公司紧抓生物医药装备行业发展机遇，持续推进市场拓展与业务布 局，收入规模稳步提升；2)受市场竞争加剧、下游行业需求波动，叠加高毛利海外收入占比下降等因素 影响，公司盈利水平有所下滑。 ...

证券代码：688755 证券简称：汉邦科技 公告编号：2026-004 江苏汉邦科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以江苏汉邦科技股份有限公司（以下简称"公司"）2025年年度报告中 披露的数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 3.以上增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 2025 年度，公司实现营业总收入 73,513.32 万元，较上年同期增长 6.40%；归 属于母公司所有者的净利润 5,958.75 万元，较上年同期下降 24.89%；归属于母公 司所有者的扣除非经常性损益的净利润 4,955.21 万元，较上年同期下降 34.84%。 2025 年末，公司总资产 193,366.32 万元，较报告期初增长 45.96%；归属于母公司 的所有者权益 1 ...

汉邦科技公告，2025年度实现营业总收入7.35亿元，同比增长6.40%；净利润5958.75万元，同比下降 24.89%。2025年末，公司总资产19.34亿元，较报告期初增长45.96%；归属于母公司的所有者权益12.43 亿元，较报告期初增长68.03%；归属于母公司所有者的每股净资产14.12元，较报告期初上升26.02%。 ...

新华财经北京2月12日电科创50指数12日以0.58%的涨幅开盘，指数盘初震荡上扬一度涨逾1%，早盘盘 中波动回落，在平盘附近完成二次下探后，指数开始震荡上行，午后涨幅持续扩大，收盘时大幅上涨。 至收盘时，科创50指数报1480.99点，涨幅1.78%，成分股总成交额约693亿元，较上一交易日大幅放 量。 科创综指12日以0.43%的涨幅开盘，指数盘初冲高回落，早盘盘中的调整并未回补与上一交易日之间缺 口，午间收盘前震荡上扬，午后最大涨幅1.78%，尾盘有所回落，收盘时显著上涨。科创综指收于 1816.15点，涨幅1.56%，总成交额约2229亿元，较上一交易日显著放量。 个股表现方面，优刻得、赛恩斯收于约20%涨停，涨幅居前；易思维下跌14.19%，跌幅居首。 成交额方面，寒武纪成交额95.02亿元，位居首位；汉邦科技成交额1028.82万元，位居末位。 换手率方面，易思维换手率为46.73%，位居首位；威高骨科换手率为0.18%，位居末位。 （文章来源：新华财经） 当日，科创板个股涨多跌少，367股收涨，占比约60.86%。细分领域中，半导体股整体涨幅靠前，软件 服务、元器件、通信设备、电气设备、专用机械 ...

Market Performance - The two major indices of the Sci-Tech Innovation Board opened significantly lower on February 6, with the Sci-Tech 50 Index dropping as much as 1.86% and the Sci-Tech Composite Index falling by 1.52% at one point [1] - By the end of the trading day, the Sci-Tech 50 Index closed at 1422.41 points, down 0.71%, with a total trading volume of approximately 623 billion yuan, showing a slight decrease compared to the previous trading day [1] - The Sci-Tech Composite Index finished at 1753.61 points, down 0.34%, with a total trading volume of about 2006 billion yuan, also reflecting a minor decline from the previous day [1][2] Stock Performance - On February 6, 277 stocks on the Sci-Tech Board rose, accounting for approximately 46.17% of the total, indicating a majority of stocks experienced declines [1] - In specific sectors, stocks related to the photovoltaic industry showed overall gains, contributing to a general rise in electrical equipment stocks, while transportation equipment stocks also saw slight increases [1] - Conversely, most software service stocks experienced declines [1] Individual Stock Highlights - Euroland New Materials saw the highest increase, rising by 12.93% [3] - Chenghe Technology recorded the largest decline, falling by 7.71% [3] Trading Activity - Cambrian's trading volume reached 82.72 billion yuan, ranking first in terms of trading volume [4] - Hanbang Technology had the lowest trading volume at 12.2789 million yuan [4] - In terms of turnover rate, Beixin Life led with a turnover rate of 44.53%, while Bairen Medical had the lowest at 0.17% [4]

Market Performance - The two major indices of the Sci-Tech Innovation Board opened significantly lower on February 5, with the Sci-Tech Comprehensive Index dropping by 2.37% at one point and the Sci-Tech 50 Index falling by 2.56% [1] - By the end of the trading day, the Sci-Tech Comprehensive Index closed at 1759.68 points, down 1.44%, with a total trading volume of approximately 211.8 billion yuan, showing a significant decrease compared to the previous trading day [1] - The Sci-Tech 50 Index reported 1432.52 points, also down 1.44%, with constituent stocks' total trading volume around 67.7 billion yuan, reflecting a notable reduction from the previous day [1] - A total of 173 stocks on the Sci-Tech Board rose, accounting for about 28.83%, while some semiconductor stocks saw significant gains in the afternoon, and the overall decline was led by electrical equipment stocks [1] Company Highlights - Beixin Life Technology Co., Ltd. is set to be listed on the Sci-Tech Innovation Board on February 6, 2026, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [2] - The company's core products include the intravascular ultrasound (IVUS) diagnostic system, which is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the blood flow reserve fraction (FFR) measurement system, which is the first domestic product in the FFR field approved by the same authority [2] - As of the close, Beixin Life's stock price increased by 183.33% from its issue price, with a trading volume of approximately 1.409 billion yuan and a turnover rate of 75.88% [2] Trading Statistics - Excluding Beixin Life's first trading day and the suspended stocks, the remaining 599 stocks on the Sci-Tech Board had an average decline of 1.02% on February 5, with an average turnover rate of 2.53% and a total trading volume of 210.413 billion yuan [2] - The average volatility for these stocks was 3.85% [2] - In individual stock performance, Guoxin Technology rose by 11.30%, leading the gains, while Dekeli fell by 11.36%, leading the losses [2]

Core Viewpoint - The Sci-Tech Innovation 50 Index experienced a decline, closing at 1453.48 points with a drop of 1.20% on February 4, 2023, amidst a total trading volume of approximately 765.9 billion yuan [1]. Group 1: Market Performance - The majority of stocks on the Sci-Tech Board saw declines, with 209 stocks rising. High-priced stocks showed mixed performance while low-priced stocks mostly increased [2]. - On average, the 600 stocks on the Sci-Tech Board experienced a decline of 0.64%, with an average turnover rate of 2.89% and a total trading volume of 242.9 billion yuan, alongside an average fluctuation of 4.16% [2]. Group 2: Individual Stock Performance - Shichuang Energy and JinkoSolar led the gainers with a rise of 20%, while Kaipu Cloud had the largest drop at 12.57% [3]. - In terms of trading volume, Cambrian Technology topped the list with a trading volume of 12.6 billion yuan, while Hanbang Technology had the lowest at 1.302 million yuan [4]. Group 3: Turnover Rate - Hengyun Chang had the highest turnover rate at 26.8%, while Bairen Medical recorded the lowest turnover rate at 0.17% [5].

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]